InflaRx (IFRX)

• Market cap: $71.8M
• 1 day: 4.95%
• 5 days: 2.91%
• 1 month: -16.54%
• 3 months: -22.63%
• 6 months: 32.83%
• Year to date: -57.6%
• 1 year: -50.93%
• 5 years: -79.34%
• 10 years: -92.93%
• Sector: Healthcare
• Industry: Biotechnology

About: InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

Employees: 74